Analysed RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) News Sources
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
16-06-2026
proactiveinvestors.com
Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?
22-06-2026
yahoo.com
Intel Stock and 3 Other Winners I Found Using Barchart’s High-Octane Stock Screener
22-06-2026
barchart.com
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
30-06-2026
yahoo.com
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
08-07-2026
yahoo.com
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
21-07-2026
yahoo.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Alphabet, Clean Harbors, Ford, Huntington Bancshares, Rivian, Rocket Lab, Terawulf, Vale, Warner Bros. Discovery, and More
27-07-2026
247wallst.com
What is the current price of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)?
The current price of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) is $107.52.
RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) absolute price change since previous trading day?
The absolute price change of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) since the previous trading day is $1.39.
RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) percentage price change since previous trading day?
The percentage price change of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) since the previous trading day is 1.3097%.
What is the most recent average sentiment score for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)?
The most recent average sentiment score for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)?
The most recent sentiment for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) is .
SEC-8K** Filing Available For RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.